UroGen Pharma Reports Third-Quarter 2026 Revenue of $89 Million
Revenue rose 223.9% from $27.48 million a year earlier as Zusduri sales grew. Net loss narrowed to $1.46 million from $33.35 million, and diluted loss per share was $0.03 versus $0.69.
UroGen Pharma reported third-quarter 2026 revenue of $89M, up 223.9% from $27.48M a year earlier, as sales of Zusduri grew. Net loss narrowed to $1.46M from $33.35M, while diluted loss per share was $0.03 compared with $0.69.Financial Highlights¹ Reported as “Revenue”. ² Reported as “Net loss”. ³ R…